Zenlabs Ethica Ltd (530697)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Zenlabs Ethica's revenue was ₹14.2 Cr (+23.5% year on year, +34.0% on the previous quarter), and net profit ₹-0.6 Cr (against a profit a year earlier); the operating margin was -2.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹14.2 | +23.5% | +34.0% |
| Operating profit | ₹-0.3 | to loss | to loss |
| Net profit | ₹-0.6 | to loss | — |
| EPS (₹) | -0.88 | to loss | — |
| Operating margin | -2.1% | — | — |
📢 Recent Corporate Announcements
Zenlabs Ethica Limited announced that shareholders approved the alteration of Clause III (B) of its Memorandum of Association (MOA) during the 33rd Annual General Meeting held on September 29, 2026. The amendment updates ancillary business objects, enabling broader contracting, foreign currency operations, R&D, and corporate structuring. The company currently has an annual revenue of Rs 46.92 Cr (FY26) and operates at a net loss (TTM PAT of Rs -3 Cr). This filing represents standard statutory enabling provisions without immediate financial outlays.
- Shareholders approved the alteration of Clause III (B) of the MOA at the 33rd AGM on September 29, 2026
- Updated clauses include terms to receive foreign currency contracts and repatriate amounts outside India
- Approval granted through a Special Resolution passed under Regulation 30 of SEBI LODR Regulations
Zenlabs Ethica Ltd has dispatched letters containing the web-link to its FY 2025-26 Annual Report to shareholders whose email addresses are not registered with the company or depositories. This filing complies with Regulation 36(1)(b) of SEBI LODR Regulations, 2015. The company's 33rd Annual General Meeting is scheduled to take place on Tuesday, September 29, 2026, at 12:00 PM IST at its registered office in Chandigarh.
- 33rd Annual General Meeting scheduled for Tuesday, September 29, 2026 at 12:00 PM IST
- Letters dispatched on September 04, 2026 providing Annual Report FY2025-26 access link
- Compliance intimation under Regulation 30 and Regulation 36(1)(b) of SEBI LODR Regulations
Zenlabs Ethica reported a revenue of ₹14.18 Cr for the quarter ended June 30, 2026, representing a 23.5% increase from ₹11.48 Cr in the same period last year. However, the company swung to a net loss of ₹0.57 Cr for the quarter, compared to a marginal profit of ₹0.03 Cr in June 2025. This loss was driven by total expenses of ₹14.73 Cr exceeding total income, largely due to a significant increase in stock-in-trade costs. With a market cap of only ₹17 Cr and a high debt-to-equity ratio of 1.29, the company's return to losses is a concern for its financial stability.
- Revenue from operations grew 23.5% YoY to ₹14.18 Cr from ₹11.48 Cr.
- Net loss for the quarter stood at ₹0.57 Cr against a profit of ₹0.03 Cr in the year-ago period.
- Total expenses rose to ₹14.73 Cr, representing 104% of total income for the quarter.
- Finance costs saw a slight reduction to ₹0.16 Cr from ₹0.21 Cr YoY.
- Basic and Diluted EPS turned negative at ₹-0.88 for the quarter.
Zenlabs Ethica reported a 23.5% YoY increase in revenue to ₹14.18 Cr for the quarter ended June 30, 2026. Despite the top-line growth, the company swung to a net loss of ₹0.57 Cr, compared to a profit of ₹0.03 Cr in the year-ago period. The loss was primarily driven by a significant increase in stock-in-trade expenses, which reached ₹4.76 Cr. With a high debt-to-equity ratio of 1.29 and a market cap of only ₹17 Cr, the company's return to profitability remains a key concern for investors.
- Revenue from operations increased to ₹1,417.66 lakhs from ₹1,147.72 lakhs YoY, a growth of 23.5%
- Net loss for the quarter stood at ₹57.12 lakhs compared to a net profit of ₹3.33 lakhs in June 2025
- Stock-in-trade expenses surged to ₹475.94 lakhs from a credit (reduction) of ₹183.01 lakhs in the previous year's quarter
- Finance costs saw a slight reduction to ₹15.70 lakhs from ₹20.76 lakhs YoY
- Basic and Diluted EPS turned negative at ₹(0.88) for the quarter
Zenlabs Ethica Ltd has entered into a sole and exclusive domestic business agreement with V Nexxtra Lifesciences Private Limited for the marketing and distribution of its entire product portfolio. Under the agreement, V Nexxtra will bear all sales, marketing, and logistics expenses, paying Zenlabs a margin of 5% on Net Sales Value for FY 2026-27, rising to 5.5% in FY 2027-28. A critical clause requires the distributor to source at least 70% of its procurement value from Zenlabs Ethica group companies, ensuring captive demand for the company's manufacturing operations.
- Appointed V Nexxtra Lifesciences as the sole and exclusive distributor for the entire Indian territory.
- Guaranteed minimum margin of 5% on Net Sales Value for FY 2026-27, payable by the 10th of each month.
- Mandatory 70% sourcing requirement from Zenlabs Ethica group companies for the distributor's total procurement.
- Distributor to bear 100% of costs related to sales teams, warehouses, and distribution centers.
- Credit period established at 75 days from the date of invoice.
Zenlabs Ethica Ltd has scheduled a board meeting for August 12, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is coming off a challenging FY26 where it reported a net loss of ₹1.94 crore on revenues of ₹46.92 crore. Investors will be monitoring if the company can improve its operating margins, which stood at a thin 3.8% for the trailing twelve months. The trading window for insiders has been closed since July 1, 2026, in compliance with SEBI regulations.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
- Trading window for insiders closed from July 1, 2026, until 48 hours post-results
- Company reported a net loss of ₹1.94 crore in the full fiscal year 2026
- TTM revenue stands at ₹47 crore against a small market capitalization of ₹18 crore
- Debt-to-equity ratio remains elevated at 1.29 as per latest available data
Zenlabs Ethica Ltd has appointed Mr. Sanjay Dhir as the Chief Financial Officer (CFO) effective July 21, 2026. This move aims to fulfill statutory requirements under Section 203 of the Companies Act, 2013. The company, a micro-cap with a market capitalization of Rs 20 Cr, is currently loss-making with a TTM PAT of Rs -2 Cr. The new CFO will be responsible for managing financial operations and strengthening governance frameworks in a period where the company faces a high debt-to-equity ratio of 1.29.
- Appointment of Mr. Sanjay Dhir as CFO effective from July 21, 2026
- Company reported TTM revenue of Rs 47 Cr against a net loss of Rs 2 Cr
- Board meeting for the appointment concluded within 30 minutes on July 22, 2026
- Current debt levels stand at Rs 11 Cr against a net worth of Rs 9 Cr
Zenlabs Ethica Ltd has appointed Mr. Sanjay Dhir as Chief Financial Officer (CFO) effective July 21, 2026, to comply with Section 203 of the Companies Act, 2013. The company is a micro-cap with a market capitalization of Rs 21 Cr and is currently facing financial pressure with a TTM net loss of Rs 2 Cr. Mr. Dhir's background in accounting and compliance will be critical as the company manages a Debt-to-Equity ratio of 1.29 and low operating margins of 3.8%.
- Appointment of Mr. Sanjay Dhir as CFO effective from July 21, 2026
- Company reported a TTM net loss of Rs 2 Cr on revenue of Rs 47 Cr
- Debt levels stand at Rs 11 Cr against a Net Worth of Rs 9 Cr
- Appointment fulfills statutory requirements under Section 203 of the Companies Act, 2013
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
